Eur J Med Chem. 2018 May 14;154:155-171. doi: 10.1016/j.ejmech.2018.05.019.
[Epub ahead of print]
Chicca A1, Arena C2, Bertini S2, Gado F2, Ciaglia E3, Abate M3, Digiacomo M2, Lapillo M2, Poli G4, Bifulco M5, Macchia M2, Tuccinardi T6, Gertsch J1, Manera C7.
Abstract
The endocannabinoid system (ECS) represents one of the major neuromodulatory systems involved in different physiological and pathological processes. Multi-target compounds exert their activities by acting via multiple mechanisms of action and represent a promising pharmacological modulation of the ECS. In this work we report 4-substituted and 4,5-disubstituted 1,2-dihydro-2-oxo-pyridine-3-carboxamide derivatives with a broad spectrum of affinity and functional activity towards both cannabinoid receptors and additional effects on the main components of the ECS. In particular compound B3 showed high affinity for CB1R (Ki = 23.1 nM, partial agonist) and CB2R (Ki = 6.9 nM, inverse agonist) and also significant inhibitory activity (IC50 = 70 nM) on FAAH with moderate inhibition of ABHD12 (IC50 = 2.5 μΜ). Compounds B4, B5 and B6 that act as full agonists at CB1R and as partial agonists (B5 and B6) or antagonist (B4) at CB2R, exhibited an additional multi-target property by inhibiting anandamide uptake with sub-micromolar IC50values (0.28-0.62 μΜ). The best derivatives showed cytotoxic activity on U937 lymphoblastoid cells. Finally, molecular docking analysis carried out on the three-dimensional structures of CB1R and CB2R and of FAAH allowed to rationalize the structure-activity relationships of this series of compounds.
KEYWORDS:
Cannabinoid receptors; Endocannabinoid system; Molecular docking; Polypharmacology; U251MG glioblastoma cell line; U937 lymphoblastoid cells
- PMID: 29793210
- DOI: 10.1016/j.ejmech.2018.05.019